Profibrotic structural and activation markers

Profibrotic structural and activation markers refer to a collective group of proteins and signaling molecules that characterize the progression of fibrotic diseases and the activation of myofibroblasts (PMID: 29408011). Structural markers primarily include components of the extracellular matrix (ECM) such as Collagen Type I, Collagen Type III, and Fibronectin, which accumulate excessively during pathological scarring. Activation markers, most notably alpha-smooth muscle actin (α-SMA), signify the phenotypic shift of resident fibroblasts into highly contractile and secretory myofibroblasts (PMID: 22414733). These markers are central to the pathology of chronic conditions affecting the lungs, liver, and kidneys, where they drive organ dysfunction (PMID: 30634440). While not a single therapeutic target, they represent the biological endpoints that anti-fibrotic drugs like Nintedanib and Pirfenidone aim to modulate (PMID: 25317870). Consequently, these markers are essential for diagnosing disease severity and monitoring the efficacy of therapeutic interventions in clinical trials.

Other names

Fibrotic markersMyofibroblast activation markersExtracellular matrix markersMarkers of fibrogenesis

Inhibition of fibroblast-to-myofibroblast transition, reduction of extracellular matrix protein synthesis, and antagonism of profibrotic growth factor signaling.